As part of our partnership with ACCRES, BDS Analytics' President and Co-Founder, Liz Stahura, recently presented a Cannabis 2.0 webinar for Canadian Retailers. Here are our Top Five takeaways:
Worldwide sales of legal cannabis re-accelerated in 2019, growing nearly 46% to almost $15 billion. The increase represents the largest yearly sales gain since Colorado launched adult-use sales in January, 2014. The growth is further magnified when compared to 2018, which only saw 17% growth.
Like many exhibitors and presenters at MJBizCon, we came away from the event invigorated by the hundreds of conversations we had with current & prospective clients. The exhibition floor was bustling, and the questions posed to us throughout the 3-day event certainly reaffirms what we already know: the industry is GROWING – but the where, who & how is still very much TBD.
The Nevada cannabis market is unique among states with legal recreational cannabis regimes. The role of tourism plays a big role in shaping retail trends. The concentration of sales in urban centers stands apart. And the state’s regulatory framework offers benefits and challenges for cannabis companies and investors.
Cannabis is perhaps the most exciting retail opportunity to hit U.S. markets in decades. The lucrative combination of rapid sales growth, an ever-expanding customer base and government-enforced protection against mass-retail has resulted in a unique market that is unlikely to be replicated anytime soon.
To some, cannabis and exercise may seem like an unlikely pairing. But those in the know understand that cannabis in its various forms can serve as a great pre, during, or post-workout supplement. These Top 5 insights from BDS Analytics counter the “lazy stoner” stereotype and show that cannabis often is a welcome addition to Consumers’ workout routines.
The latest Cannabis Intelligence Briefing from Arcview Market Research and BDS Analytics: CBD: Cannabidiol Escapes the Dispensary details CBD’s move from legal cannabis dispensaries to the general retail market. At present, the bulk (65%) of the $1.9 billion in annual spending on CBD products in the U.S. takes place through licensed dispensaries in legal cannabis states.
CBD: it spans product categories, retail channels, regulatory landscapes – and even species. Last month’s webinar covered the current cannabinoid market as it relates to pain management as well as pet care, both within the dispensary channel (CBD from marijuana) and in the general retail market (hemp-derived CBD). While pain management and pet care might seem like disparate angles from which to talk about cannabinoids, they actually do have some common ground. The wellness market is booming, as consumers’ approach to health care shifts; similarly, the pet industry has grown consistently as pets take on an increasingly heightened role in the American household. Both cannabinoid-based pain and pet products cross retail channels, with availability in medical and adult-use dispensaries as well as across general market retail channels. And, across pain management and pet care, cannabinoid-based products are a welcome supplement (or alternative) to other forms of medical or wellness-based solutions. Here we’ll look at some of the main takeaways from the webinar – but for the full story, you can watch the presentation and download the deck here.
We’re in no rush to say goodbye to summer, but, as we head into Labor Day weekend, let’s review how the cannabis industry has fared during Labor Day weekends past and other key summer holiday periods:
Our August webinar, Pet, Pain, and CBD: The Many Applications of Cannabinoid Products is coming up this week. Here is some of what you can expect to learn – be sure to tune in on Thursday for the full story. Register here: http://bit.ly/2MRJQbU